AASLD: HCV Testing by Birth Cohort Cost-Effective (CME/CE)

SAN FRANCISCO (MedPage Today) — Birth-cohort screening for hepatitis C virus infection proved highly cost-effective, even when universal treatment with direct-acting antiviral therapy was factored in, according to a study reported here.

Post a Comment

Comments are closed.